Complete Guide to Garsorasib Resistance Mechanisms and Follow-Up Treatments

　　1.Overview of Resistance

　　Garsorasib is a next-generation KRAS G12C covalent inhibitor indicated for the treatment of patients with advanced non-small cell lung cancer(NSCLC)and colorectal cancer(CRC)harboring KRAS G12C mutations.Despite its promising initial response with an objective response rate(ORR)of approximately 35%-45%,the vast majority of patients develop acquired resistance within 6 to 12 months of treatment,leading to disease progression.In-depth analysis of resistance mechanisms and development of targeted subsequent strategies are core to optimizing clinical management for these patients.

　　2.Common Acquired Resistance Mechanisms

　　Acquired resistance to KRAS G12C inhibitors is mainly classified into four categories:

　　On-target mutations:Secondary mutations in the KRAS G12C gene,such as Y96D,R68S,and H95Q,alter the protein conformation and prevent covalent binding of Garsorasib to its target,resulting in drug failure.

　　Bypass activation:Amplification or activation of other receptor tyrosine kinases(RTKs)such as EGFR,MET,HER2,and FGFR bypasses the inhibited KRAS signaling pathway and continuously drives tumor cell proliferation.Among these,MET amplification is the most common bypass resistance mechanism,occurring in approximately 20%of resistant patients.

　　Downstream pathway activation:Mutations in signaling molecules downstream of KRAS,such as BRAF V600E and MAP2K1(MEK1)mutations,lead to persistent activation of the MAPK pathway independent of upstream KRAS inhibition.

　　Phenotypic transformation:Tumor cells undergo epithelial-mesenchymal transition(EMT)or,in rare cases,transform to small cell lung cancer,thereby acquiring resistance to KRAS G12C inhibitors.

　　3.Standardized Diagnostic Process After Resistance

　　When patients develop radiographic disease progression,repeat tissue biopsy or circulating tumor DNA(ctDNA)next-generation sequencing(NGS)testing is strongly recommended.Testing should comprehensively cover:the retention status of KRAS G12C mutations,the presence of on-target secondary mutations,and other potential driver gene abnormalities(such as MET,EGFR,BRAF,etc.).ctDNA testing offers the advantages of non-invasiveness and dynamic monitoring,and can typically predict resistance 2-3 months earlier than imaging,allowing for early intervention.

　　4.Individualized Subsequent Treatment Strategies Based on Resistance Mechanisms

　　Differentiated treatment regimens are required for different resistance mechanisms:

　　On-target Y96D mutation:This is one of the most common on-target resistance mutations.Studies have shown that the Y96D mutation confers complete resistance to Garsorasib,cross-resistance to Adagrasib,and partial resistance to MRTX-849.Patients with this mutation may consider KRAS G12C degraders(such as RMC-6291)or SOS1 inhibitors.

　　MET amplification:Combination therapy with Garsorasib and a MET inhibitor(such as Capmatinib,Savolitinib)is recommended.Multiple case reports and clinical studies have shown that combination therapy can re-induce disease responses in some patients.

　　EGFR activation:A regimen of Garsorasib combined with Osimertinib or Afatinib may be used.Close monitoring for overlapping toxicities and timely dose adjustment are required during treatment.

　　BRAF V600E mutation:Combination therapy with Dabrafenib and Trametinib dual-targeted regimen is recommended.

　　No identifiable resistance mechanism:For patients without detectable driver gene abnormalities,standard chemotherapy regimens(such as Docetaxel plus Ramucirumab)may be used.If patients have high PD-L1 expression,immune monotherapy or combination immunotherapy may also be considered.

　　5.Value of Switching to Other KRAS G12C Inhibitors

　　Although there is some degree of cross-resistance between different KRAS G12C inhibitors,some patients may still benefit from switching from Garsorasib to Adagrasib,especially those with resistance due to insufficient drug exposure rather than genetic alterations.Due to differences in drug inhibition kinetics and tissue distribution characteristics between the two agents,clinical trial data show that approximately 30%of patients who switch achieve partial responses.

　　6.Exploration of Cutting-Edge Combination Therapy Regimens

　　Numerous clinical trials are currently underway worldwide to explore combination therapy strategies that can overcome Garsorasib resistance,mainly including:

　　Garsorasib plus EGFR inhibitor(Cetuximab):This regimen has shown significant efficacy in colorectal cancer patients by effectively blocking resistance caused by feedback EGFR activation.

　　Garsorasib plus SHP2 inhibitor(such as TNO155):Enhances tumor cell inhibition by blocking upstream signaling of KRAS,with relevant clinical trials ongoing.

　　Garsorasib plus chemotherapy(Pemetrexed/Carboplatin):Indicated for patients with rapidly progressive disease who require rapid symptom control.

　　7.Clinical Trial Opportunities

　　For patients who have developed resistance after multiple lines of treatment and have limited standard treatment options,active participation in clinical trials is an important therapeutic choice.Ongoing studies include KRAS G12C protein degraders(PROTAC technology),fourth-generation KRAS inhibitors(such as BI-3406),and various combination immunotherapy regimens.Patients can query relevant research information through global clinical trial databases.

　　8.Patient Support and Quality of Life Management

　　Patients often face significant psychological stress after developing resistance,and adequate psychological support and counseling should be provided.At the same time,active management of tumor-related symptoms such as pain and dyspnea is necessary,and palliative care should be introduced when needed to improve patients'quality of life.With the rapid development of the KRAS targeted therapy field,more and more novel drugs and treatment regimens will gradually enter clinical practice,bringing new hope to patients.

　　9.Conclusion

　　Resistance to Garsorasib is not the end of treatment,but an important node for adjusting treatment strategies.In clinical practice,comprehensive genetic testing must be performed to clarify the resistance mechanism,and then individualized treatment regimens based on the mechanism should be formulated,including switching to next-generation targeted drugs,combining with inhibitors of other pathways,or participating in clinical trials.With the continuous in-depth research on the KRAS signaling pathway,more effective therapeutic tools will be available to overcome resistance and prolong patient survival in the future.